Effectiveness of combined modality radiotherapy of orthotopic human squamous cell carcinomas in Nu/Nu mice using cetuximab, tirapazamine and MnSOD-plasmid liposome gene therapy

In Vivo

Volumn 24, Issue 1, 2010, Pages 1-8

  Epperly, Michael W ^a   Lai, Stephen Y ^a   Kanai, Anthony J ^b   Mason, Neal ^b   Lopresi, Brian ^b   Dixon, Tracey ^a   Franicola, Darcy ^a   Nui, Yunyun ^a   Wilson, William R ^c   Greenberger, Joel S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cetuximab; MnSOD PL; Orthotopic tumors; Tirapazamine

Indexed keywords

CETUXIMAB; LIPOSOME; MANGANESE SUPEROXIDE DISMUTASE; TIRAPAZAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; GENE THERAPY; HISTOPATHOLOGY; MOUSE; MOUTH CARCINOMA; NONHUMAN; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

EID: 77649084590     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Agarwala SS, Cano E, Heron DE, Johnson J, Myers E, Sandulache V, Bahri S, Ferris R, Wang Y and Argiris A: Longterm outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. Annals of Oncology 18: 1224-1229, 2007.
2. Le QT, Taira A, Budenz S et al: Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas. Cancer 106: 1940-1949, 2006.
3. Kam MKM, Leung S-F, Zee B, Chau RMC, Suen JJS, Mo F, Lai M, Ho R, Cheung K-Y, Yu BKH, Chiu SKW, Choi PHK, Teo PML, Kwan W-H and Chan ATC: Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25(31): 4873-4879, 2007.
4. Eisbruch A: Reducing xerostomia by IMRT: What may, and may not, be achieved. J Clin Oncol 25(31): 4863-4864, 2007.
5. Yao M, Karnell LH, Funk GF, Lu H, Dornfeld K and Buatti JM: Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. Int J Rad Oncol Biol Phys 69(5): 1354-1360, 2007.
6. Thariat J, Milas L and Ang KK: Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 69(4): 974-984, 2007.
7. Bonner JA, Harari PM, Giralt J et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6): 567-578, 2006.
8. Irmer D, Funk JO and Blaukat A: EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy. Oncogene 26: 5693-5701, 2007.
9. Dent P, Reardon DB, Park JS, Bower G, Logsdon C, Valerie K and Schmidt-Ullrich R: Radiation-induced release of transforming growth factor α activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10: 2493-2506, 1999.
10. Fischel J-L, Formento P and Milano G: Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab) impact on cell growth and molecular factors. Br J Cancer 92: 1063-1068, 2005.
11. Shibuya K, Komaki R, Shintani T, Itasaka S, Anderson R, Jurgensmeier JM, Milas L, Ang K, Herbst RS and O'Reilly MS: Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small cell lung cancer. Int J Radiat Oncol Biol Phys 69(5): 1534-1543, 2007.
12. Kip2 cell-cycle regulator through degradation of EGFR1. Proc Nat Acad Sci USA 104(46): 18085-18090, 2007.
13. Brown JM and Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447, 2004.
14. Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K and Wilson WR: Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiation Oncology Biol Phys 69(2): 560-571, 2007.
15. 15,Rischin D, Peters I, Hicks R et al: Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19: 535-542, 2001.
16. Zagorevskii D, Song M, Breneman C et al: A mass spectrometry study of tirapazamine and its metabolites: insights into the mechanism of metabolic transformations and the characterization of reaction intermediates. J Am Soc Mass Spectrom 14: 881-892, 2003.
17. Anderson RF, Shinde SS, Hay MP, Gamage SA and Denny WA: Activation of 3-amino-1, 2, 4-benzotriazine 1, 4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J Am Chem Soc 125: 748-756, 2003.
18. Palmer LA, Doctor A, Chhabra P, Sheram ML, Laubach VE, Karlinsey MZ, Forbes MS, Macdonald T and Gaston B: S-Nitrosothiols signal hypoxia-mimetic vascular pathology. J Clin Invest 117(9): 2592-2600, 2007.
19. Rischin D, Peters L, Fisher R et al: Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23: 79-87, 2005.
20. von Pawel J, von Roemeling R, Gatzemeier U et al: Tirapazamine plus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. J Clin Oncol 18: 1351-1359, 2000.
21. Law A, Kennedy T, Pellitteri P, Wood C, Christie D, and Yumen O: Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 69(5): 1361-1368, 2007.
22. Chambers MS, Jones CU, Biel MA, Weber RS, Hodge KM, Chen Y, Holland JM, Ship JA, Vitti R, Armstrong I, Garden AS and Haddad R: Open-label, long-term safety study of cevimeline in the treatment of post irradiation xerostomia. Int J Radiat Oncol Biol Phys 69(5): 1369-1376, 2007.
23. Jeschke MG, Richter G, Hofstadter F, Herndon DN, Perez-Polo J-R and Jauch K-W: Non-viral liposomal keratinocyte growth factor (KGF) cDNA gene transfer improves dermal and epidermal regeneration through stimulation of epithelial and mesenchymal factors. Gene Ther 9: 1065-1074, 2002.
24. Phillips TL, Kane L and Utley JF: Radioprotection of tumor and normal tissues by thiophosphate compounds. Cancer 32: 528-535,1973.
25. Newton GL,Aguilera JA, Kim T, Ward JF and Fahey RC: Transport of aminothiol radioprotectors into mammalian cells: passive diffusion versus mediated uptake. Radiat Res 146: 206-215,1996.
26. Rube CE, Wilfert F, Uthe D, Schmid KW, Knoop R, Willich N, Schuck A and Rube C: Modulation of radiation-induced tumour necrosis factor α (TNF-α) expression in the lung tissue by pentoxifylline. Radiother Oncol 64: 177-187, 2002.
27. Werner-Wasik M, Axelrod RS, Friedland DP, Hauck W, Rose LJ, Chapman AE, Grubbs S, DeShields M and Curran WJ: Preliminary report on reduction of esophagitis by amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy. Clin Lung Cancer 2(4): 284-289,2001.
28. Wasserman TH and Brizel DM: The role of amifostine as a radioprotector. Oncology 15(10): 1349-1354, 2001.
29. Tretter L, Ronai E, Szabados G, Hermann R, Ando A and Horvath I: The effect of the radioprotector WR-2721 and WR-1065 on mitochondrial lipid peroxidation. Int J Radiat Biol 57: 467-478, 1990.
30. Wong GHW: Protective roles of cytokines against radiation: Induction of mitochondrial MnSOD. Biochim Biophys Acta 1271: 205-209, 1995.
31. Stickle RL, Epperly MW, Klein E, Bray JA and Greenberger JS: Prevention of irradiation-induced esophagitis by plasmid/liposome delivery of the human manganese superoxide dismutase (MnSOD) transgene. Radiat Oncol Invest Clin Basic Res 7(6): 204-217,1999.
32. Epperly MW, Defilippi S, Sikora C, Gretton J, Kalend K and Greenberger JS: Intratracheal injection of manganese superoxide dismutase (MnSOD) plasmid/liposomes protects normal lung but not orthotopic tumors from irradiation. Gene Ther 7(12): 1011-1018, 2000.
33. Epperly MW, Gretton JA, Defilippi SJ, Sikora CA, Liggitt D, Koe G and Greenberger JS: Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (SOD-PL) gene therapy. Radiat Res 155: 2-14, 2001.
34. Epperly MW, Kagan VE, Sikora CA, Gretton JE, Defilippi SJ, Bar-Sagi D and Greenberger JS: Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) administration protects mice from esophagitis associated with fractionated irradiation. Int J Cancer (Radiat Oncol Invest) 96(4): 221-233, 2001.
35. Epperly MW, Sikora C, Defilippi S, Gretton J, Zhan Q, Kufe DW and Greenberger JS: MnSOD inhibits irradiation-induced apoptosis by stabilization of the mitochondrial membrane against the effects of SAP kinases p38 and Jnk1 translocation. Radiat Res 157: 568-577, 2002.
36. Guo HL, Seixas-Silva JA, Epperly MW, Gretton JE, Shin DM and Greenberger JS: Prevention of irradiation-induced oral cavity mucositis by plasmid/liposome delivery of the human manganese superoxide dismutase (MnSOD) transgene. Radiat Res 159: 361-370, 2003.
37. Guo HL, Epperly MW, Bernarding M, Nie S, Gretton J, Jefferson M and Greenberger JS: Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) intratracheal gene therapy reduction of irradiation-induced inflammatory cytokines does not protect orthotopic Lewis lung carcinomas. In Vivo 17: 13-22, 2003.
38. Epperly MW, Carpenter M, Agarwal A, Mitra P, Nie S and Greenberger JS: Intra-oral manganese superoxide dismutase plasmid/liposome radioprotective gene therapy decreases ionizing irradiation-induced murine mucosal cell cycling and apoptosis. In Vivo 18: 401-410, 2004.
39. Epperly MW, Wegner R, Kanai AJ, Kagan V, Greenberger EE, Nie S and Greenberger JS: Irradiated murine oral cavity orthotopic tumor antioxidant pool destabilization by MnSOD-plasmid liposome gene therapy mediates tumor radiosensitization. Radiat Res 267: 289-297, 2007.
40. Chancellor MB, Tirney S, Mattes CE, Tzeng E, Birder LA, Kanai AJ, de Groat WC, Huard, J, and Yoshimura N: Nitric oxide synthase gene transfer for erectile dysfunction in a rat model. BJU Int 91(7): 691-696, 2003.
41. 18F] fluorodeoxy-glucose positron-emission tomography imaging. Clin Can Res 10: 2245-2252, 2004.
42. Epperly MW, Franicola D, Zhang X, Nie S and Greenberger JS: Effect of EGFR receptor antagonists gefitinib (Iressa) and C225 (Cetuximab) on MnSOD-Plasmid Liposome transgene radiosensitization of a murine squamous cell carcinoma cell line. In Vivo 20: 791-796,2006.
43. Zhang X, Epperly MW, Kay MA, Chen Z-Y, Smith T, Franicola D, Greenberger BA, Komanduri P and Greenberger JS: Radioprotection in vitro and in vivo by mini circle plasmid carrying the human manganese superoxide dismutase transgene. Hum Gene Ther 19: 820-826, 2008.